{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T04:04:53Z","timestamp":1750737893942,"version":"3.41.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Egyptian Russian University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Recently, men with overactive bladder have been prescribed mirabegron and tamsulosin for the treatment of benign prostatic hyperplasia. Highly efficient and environmentally sustainable spectrophotometric methods have been developed for the accurate determination of mirabegron and tamsulosin in their pure forms as well as within pharmaceutical formulations. This study presents three effective and simple spectrophotometric methods for the simultaneous quantification of mirabegron and tamsulosin. The current protocols have demonstrated validation for linearity across concentration ranges of 3\u201320\u00a0\u00b5g\/mL for mirabegron and 2\u201340\u00a0\u00b5g\/mL for tamsulosin, utilizing dual wavelength, ratio difference, and derivative ratio techniques. The coefficients of determination exceeded 0.999. The validation of these methodologies was conducted in accordance with the guidelines set forth by the International council for Harmonization (ICH). Quality control laboratories may utilize existing techniques to identify the binary combination because of their high accuracy and cheap cost. The evaluation of the environmental sustainability of the established approaches was conducted using AGREE, GAPI, MOGAPI and whiteness revealing their notable eco-friendliness. The proposed method was deemed practical after the evaluation carried out with the Blue Applicability Grade Index (BAGI) assessment.<\/jats:p>","DOI":"10.1038\/s41598-025-06157-9","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T15:55:17Z","timestamp":1750694117000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Eco-friendly spectrophotometric quantification of the potential combination of mirabegron and tamsulosin"],"prefix":"10.1038","volume":"15","author":[{"given":"Omar M","family":"El-Abassy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanaa","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Islam M.","family":"Darwish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman A.","family":"Bahgat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"key":"6157_CR1","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/bph.13367","volume":"173","author":"EC Alexandre","year":"2016","unstructured":"Alexandre, E. C. et al. Mirabegron relaxes urethral smooth muscle by a dual mechanism involving \u03b23-adrenoceptor activation and \u03b11\u2010adrenoceptor Blockade. Br. J. Pharmacol. 173, 415\u2013428. https:\/\/doi.org\/10.1111\/bph.13367 (2016).","journal-title":"Br. J. Pharmacol."},{"key":"6157_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1159\/000447205","volume":"11","author":"E Leron","year":"2018","unstructured":"Leron, E., Weintraub, A. Y., Mastrolia, S. A. & Schwarzman, P. Overactive bladder syndrome: evaluation and management. Curr. Urol. 11, 117\u2013125. https:\/\/doi.org\/10.1159\/000447205 (2018).","journal-title":"Curr. Urol."},{"key":"6157_CR3","first-page":"S580","volume":"6","author":"P Abrams","year":"2000","unstructured":"Abrams, P., Kelleher, C. J., Kerr, L. A. & Rogers, R. G. Overactive bladder significantly affects quality of life. Am. J. Manag Care. 6, S580\u2013S590 (2000).","journal-title":"Am. J. Manag Care"},{"key":"6157_CR4","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","volume":"87","author":"I Milsom","year":"2001","unstructured":"Milsom, I. et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 87, 760\u2013766. https:\/\/doi.org\/10.1046\/j.1464-410x.2001.02228.x (2001).","journal-title":"BJU Int."},{"key":"6157_CR5","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","volume":"20","author":"WF Stewart","year":"2003","unstructured":"Stewart, W. F. et al. Prevalence and burden of overactive bladder in the united States. World J. Urol. 20, 327\u2013336. https:\/\/doi.org\/10.1007\/s00345-002-0301-4 (2003).","journal-title":"World J. Urol."},{"key":"6157_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/etm.2021.10879","volume":"22","author":"I Scarneciu","year":"2021","unstructured":"Scarneciu, I. et al. Overactive bladder: A review and update. Exp. Ther. Med. 22, 1\u20138. https:\/\/doi.org\/10.3892\/etm.2021.10879 (2021).","journal-title":"Exp. Ther. Med."},{"key":"6157_CR7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","volume":"61","author":"P Abrams","year":"2003","unstructured":"Abrams, P. et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the international continence society. Eur. Urol. 61, 37\u201349. https:\/\/doi.org\/10.1016\/S0090-4295(02)02243-4 (2003).","journal-title":"Eur. Urol."},{"key":"6157_CR8","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.eururo.2014.12.038","volume":"67","author":"C Gratzke","year":"2015","unstructured":"Gratzke, C. et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur. Urol. 67, 1099\u20131109. https:\/\/doi.org\/10.1016\/j.eururo.2014.12.038 (2015).","journal-title":"Eur. Urol."},{"key":"6157_CR9","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1007\/s00345-019-03040-x","volume":"38","author":"EE Helou","year":"2020","unstructured":"Helou, E. E. et al. The use of mirabegron in neurogenic bladder: a systematic review. World J. Urol. 38, 2435\u20132442. https:\/\/doi.org\/10.1007\/s00345-019-03040-x (2020).","journal-title":"World J. Urol."},{"key":"6157_CR10","doi-asserted-by":"publisher","first-page":"110258","DOI":"10.1016\/j.microc.2024.110258","volume":"200","author":"EA Bahgat","year":"2024","unstructured":"Bahgat, E. A., Saleh, H., Hendawy, H. A. M. & Darwish, I. M. Challenging electroanalytical method for the determination of mirabegron in biological samples and pharmaceutical formulations. Microchem. J. 200, 110258. https:\/\/doi.org\/10.1016\/j.microc.2024.110258 (2024).","journal-title":"Microchem. J."},{"key":"6157_CR11","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1002\/jssc.202100980","volume":"45","author":"EB Kamel","year":"2022","unstructured":"Kamel, E. B. Two green chromatographic methods for the quantification of Tamsulosin and Solifenacin along with four of their impurities. J. Sep. Sci. 45, 1305\u20131316. https:\/\/doi.org\/10.1002\/jssc.202100980 (2022).","journal-title":"J. Sep. Sci."},{"key":"6157_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1756287220974130","volume":"12","author":"TW Kang","year":"2020","unstructured":"Kang, T. W. & Chung, H. C. Add-on treatment with mirabegron May improve quality of life in patients with benign prostatic hyperplasia complaining of persistent storage symptoms after Tamsulosin monotherapy. Ther. Adv. Urol. 12, 1\u20137. https:\/\/doi.org\/10.1177\/1756287220974130 (2020).","journal-title":"Ther. Adv. Urol."},{"key":"6157_CR13","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.3390\/ph16101457","volume":"16","author":"W Shin","year":"2023","unstructured":"Shin, W., Yang, A. Y., Yoo, H. & Kim, A. Drug\u2013Drug interactions between Tamsulosin and mirabegron in healthy individuals do not affect pharmacokinetics and hemodynamic parameters significantly. Pharmaceuticals 16, 1457. https:\/\/doi.org\/10.3390\/ph16101457 (2023).","journal-title":"Pharmaceuticals"},{"key":"6157_CR14","doi-asserted-by":"publisher","unstructured":"Mishra, S., Surekha, N. & Chauhan, A. Development and validation of stability indicating RP-HPLC method for simultaneous estimation of silodosin and mirabegron in synthetic mixture, in: Ann Pharm Fr, Elsevier, : pp. 243\u2013262. (2024). https:\/\/doi.org\/10.1016\/j.pharma.2023.12.013","DOI":"10.1016\/j.pharma.2023.12.013"},{"key":"6157_CR15","doi-asserted-by":"publisher","first-page":"115937","DOI":"10.1016\/j.jpba.2023.115937","volume":"240","author":"Y Lou","year":"2024","unstructured":"Lou, Y. et al. Simultaneous quantification of mirabegron and vibegron in human plasma by HPLC-MS\/MS and its application in the clinical determination in patients with tumors associated with overactive bladder. J. Pharm. Biomed. Anal. 240, 115937. https:\/\/doi.org\/10.1016\/j.jpba.2023.115937 (2024).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"6157_CR16","doi-asserted-by":"publisher","unstructured":"Kadam, M. M. M., Singh, R. P. & Charde, M. S. Development and validation of stability indicating UHPLC method for the quantitative Estimation of mirabegron and Solifenacin succinate in pharmaceutical dosage form. J. Pharm. Negat. Results. 6727\u20136737. https:\/\/doi.org\/10.47750\/pnr.2022.13.S07.815 (2023).","DOI":"10.47750\/pnr.2022.13.S07.815"},{"key":"6157_CR17","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.14704\/nq.2022.20.9.NQ44310","volume":"20","author":"G Andhale","year":"2022","unstructured":"Andhale, G., Shankarpure, M., Kadam, J., Shelar, M. & Singh, S. RP-HPLC method development and validation for the simultaneous Estimation of mirabegron and Solifenacin succinate in pharmaceutical dosage form. NeuroQuantology 20, 2652. https:\/\/doi.org\/10.14704\/nq.2022.20.9.NQ44310 (2022).","journal-title":"NeuroQuantology"},{"key":"6157_CR18","first-page":"36","volume":"1","author":"M Rezaei","year":"2018","unstructured":"Rezaei, M. & Ramazani, A. RP-HPLC method development and validation for the quantitative Estimation of mirabegron in extended-release tablets. J. Med. Chem. Sci. 1, 36\u201340 (2018).","journal-title":"J. Med. Chem. Sci."},{"key":"6157_CR19","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10337-016-3210-1","volume":"80","author":"AM Yehia","year":"2017","unstructured":"Yehia, A. M., Sami, I., Riad, S. M. & El-Saharty, Y. S. Comparison of two stability-indicating chromatographic methods for the determination of mirabegron in presence of its degradation product. Chromatographia 80, 99\u2013107. https:\/\/doi.org\/10.1007\/s10337-016-3210-1 (2017).","journal-title":"Chromatographia"},{"key":"6157_CR20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jchromb.2012.01.018","volume":"887","author":"R Van Teijlingen","year":"2012","unstructured":"Van Teijlingen, R. et al. Development and validation of LC\u2013MS\/MS methods for the determination of mirabegron and its metabolites in human plasma and their application to a clinical Pharmacokinetic study. J. Chromatogr. B. 887, 102\u2013111. https:\/\/doi.org\/10.1016\/j.jchromb.2012.01.018 (2012).","journal-title":"J. Chromatogr. B"},{"key":"6157_CR21","doi-asserted-by":"publisher","first-page":"409","DOI":"10.17628\/ecb.2019.8.409-415","volume":"8","author":"JN Sangshetti","year":"2019","unstructured":"Sangshetti, J. N., Chivte, D. K., Imran, M. & Mahaparale, P. Development of Hplc method for determination of Tamsulosin using quality by design (QBD) approach. Eur. Chem. Bull. 8, 409\u2013414. https:\/\/doi.org\/10.17628\/ecb.2019.8.409-415 (2019).","journal-title":"Eur. Chem. Bull."},{"key":"6157_CR22","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2174\/1573412911666151026220542","volume":"12","author":"RA Afshari","year":"2016","unstructured":"Afshari, R. A. & Qomi, M. A novel application of three phase Hollow fiber based liquid phase Microextraction (HF-LPME) for the HPLC determination of Tamsulosin from biological fluids. Curr. Pharm. Anal. 12, 258\u2013265 (2016).","journal-title":"Curr. Pharm. Anal."},{"key":"6157_CR23","doi-asserted-by":"publisher","first-page":"840","DOI":"10.4236\/ajac.2016.711073","volume":"7","author":"HKR Ganthi","year":"2016","unstructured":"Ganthi, H. K. R. et al. Stability indicating HPLC method for quantification of Solifenacin succinate & Tamsulosin hydrochloride along with its impurities in tablet dosage form. Am. J. Analyt Chem. 7, 840\u2013862. https:\/\/doi.org\/10.4236\/ajac.2016.711073 (2016).","journal-title":"Am. J. Analyt Chem."},{"key":"6157_CR24","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1080\/10826076.2013.778637","volume":"37","author":"MK Nasare","year":"2014","unstructured":"Nasare, M. K. et al. Simultaneous determination of finasteride and Tamsulosin in combined dosage form by using RP-HPLC method. J. Liq Chromatogr. Relat. Technol. 37, 1176\u20131186. https:\/\/doi.org\/10.1080\/10826076.2013.778637 (2014).","journal-title":"J. Liq Chromatogr. Relat. Technol."},{"key":"6157_CR25","unstructured":"Ishaq, B. M., Prakash, K. V. & Mohan, G. K. Simultaneous determination of dutasteride and tamsulosin in pharmaceutical dosage forms by RP-HPLC, in: International Conference on Harmonization (ICH) Analytical Method Validation Guidelines, : p. 16. (2014)."},{"key":"6157_CR26","doi-asserted-by":"publisher","first-page":"255","DOI":"10.4103\/0976-0105.103817","volume":"3","author":"GS Kumar","year":"2012","unstructured":"Kumar, G. S. & Kumar, B. S. P. Stability-indicating RP-HPLC method for determination of Tamsulosin Hcl in pharmaceutical dosage form. J. Basic. Clin. Pharm. 3, 255. https:\/\/doi.org\/10.4103%2F0976-0105.103817 (2012).","journal-title":"J. Basic. Clin. Pharm."},{"key":"6157_CR27","first-page":"319","volume":"4","author":"SM Mhamunkar","year":"2012","unstructured":"Mhamunkar, S. M., Vyavaharkar, R. Y. & Bhoir, S. I. RP-HPLC method development and validation for the simultaneous Estimation of Tamsulosin HCl and Tolterodine tartrate in pharmaceutical dosage form. Int. J. Pharm. Pharm. Sci. 4, 319\u2013322 (2012).","journal-title":"Int. J. Pharm. Pharm. Sci."},{"key":"6157_CR28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jchromb.2012.10.012","volume":"909","author":"CI Choi","year":"2012","unstructured":"Choi, C. I. et al. Determination of Tamsulosin in human plasma by liquid chromatography\/tandem mass spectrometry and its application to a Pharmacokinetic study. J. Chromatogr. B. 909, 65\u201369. https:\/\/doi.org\/10.1016\/j.jchromb.2012.10.012 (2012).","journal-title":"J. Chromatogr. B"},{"key":"6157_CR29","first-page":"79","volume":"3","author":"MK Thimmaraju","year":"2011","unstructured":"Thimmaraju, M. K., Rao, V. & Gurrala, S. RP HPLC method for the determination of finasteride and Tamsulosin in bulk and pharmaceutical formulations. Pharm. Lett. 3, 79\u201386 (2011).","journal-title":"Pharm. Lett."},{"key":"6157_CR30","doi-asserted-by":"publisher","first-page":"785","DOI":"10.4103\/0250-474X.84596","volume":"72","author":"R Kumari","year":"2010","unstructured":"Kumari, R., Dash, P. P., Lal, V. K., Mishra, A. & Murthy, P. N. RP\u2013HPLC method for the Estimation of Tamsulosin hydrochloride in tablet dosage form. Indian J. Pharm. Sci. 72, 785. https:\/\/doi.org\/10.4103%2F0250-474X.84596 (2010).","journal-title":"Indian J. Pharm. Sci."},{"key":"6157_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13065-023-01043-9","volume":"17","author":"MM Abou El-Alamin","year":"2023","unstructured":"Abou El-Alamin, M. M., Toubar, S. S., Mohamed, D. A. & Helmy, M. I. Development of green HPTLC method for simultaneous determination of a promising combination Tamsulosin and mirabegron: stability-indicating assay was examined. BMC Chem. 17, 1\u201318. https:\/\/doi.org\/10.1186\/s13065-023-01043-9 (2023).","journal-title":"BMC Chem."},{"key":"6157_CR32","doi-asserted-by":"publisher","unstructured":"Bahgat, E. A., Saleh, H., Darwish, I. M. & El-Abassy, O. M. Green HPLC technique development for the simultaneous determination of the potential combination of mirabegron and Tamsulosin. Sci. Rep. 15 https:\/\/doi.org\/10.1038\/s41598-025-89216-5 (2025).","DOI":"10.1038\/s41598-025-89216-5"},{"key":"6157_CR33","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1093\/jaoacint\/qsad029","volume":"106","author":"EA Bahgat","year":"2023","unstructured":"Bahgat, E. A., Hashem, H., Saleh, H., Kamel, E. B. & Eissa, M. S. Manipulation and processing of spectral signals for the assay of the newly authorized mixture of bupivacaine\/meloxicam using fully green solvents and a comparative green evaluation supporting the greenness and sustainability of the developed smart spectro. J. AOAC Int. 106, 1056\u20131069. https:\/\/doi.org\/10.1093\/jaoacint\/qsad029 (2023).","journal-title":"J. AOAC Int."},{"key":"6157_CR34","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1093\/jaoacint\/qsac143","volume":"106","author":"MM Elhassan","year":"2023","unstructured":"Elhassan, M. M., Mahmoud, A. M., Hegazy, M. A. & Mowaka, S. Univariate and multivariate determination of Dapagliflozin and saxagliptin in bulk and dosage form. J. AOAC Int. 106, 794\u2013803. https:\/\/doi.org\/10.1093\/jaoacint\/qsac143 (2023).","journal-title":"J. AOAC Int."},{"key":"6157_CR35","doi-asserted-by":"publisher","first-page":"117429","DOI":"10.1016\/j.saa.2019.117429","volume":"224","author":"MM Sebaiy","year":"2020","unstructured":"Sebaiy, M. M., Sobhy, M. & Mattar, A. A. Different techniques for overlapped UV spectra resolution of some co-administered drugs with Paracetamol in their combined pharmaceutical dosage forms. Spectrochim Acta Mol. Biomol. Spectrosc. 224, 117429. https:\/\/doi.org\/10.1016\/j.saa.2019.117429 (2020).","journal-title":"Spectrochim Acta Mol. Biomol. Spectrosc."},{"key":"6157_CR36","unstructured":"Step & ICH Q2 (R2. November) VALIDATION OF ANALYTICAL PROCEDURES: Text and methodology (2023). www.ema.europa.eu\/contact"},{"key":"6157_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13065-022-00860-8","volume":"16","author":"H Ibrahim","year":"2022","unstructured":"Ibrahim, H., El-Abassy, O. M., Abdellatef, H. E., Hendawy, H. A. M. & El-Sayed, H. M. Simultaneous analysis of two drugs used as supportive treatment for COVID-19: comparative statistical studies and analytical ecological appraisal. BMC Chem. 16, 1\u201315. https:\/\/doi.org\/10.1186\/s13065-022-00860-8 (2022).","journal-title":"BMC Chem."},{"key":"6157_CR38","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3390\/separations9020049","volume":"9","author":"AE Ibrahim","year":"2022","unstructured":"Ibrahim, A. E. et al. Eco-friendly and sensitive HPLC and TLC methods validated for the determination of betahistine in the presence of its process-related impurity. Separations 9, 49. https:\/\/doi.org\/10.3390\/separations9020049 (2022).","journal-title":"Separations"},{"key":"6157_CR39","doi-asserted-by":"publisher","first-page":"120436","DOI":"10.1016\/j.saa.2021.120436","volume":"266","author":"MS Elmasry","year":"2022","unstructured":"Elmasry, M. S., Hassan, W. S., El-Mammli, M. Y. & Badrawy, M. Earth friendly spectrophotometric methods based on different manipulation approaches for simultaneous determination of aspirin and Omeprazole in binary mixture and pharmaceutical dosage form: comparative statistical study. Spectrochim Acta Mol. Biomol. Spectrosc. 266, 120436. https:\/\/doi.org\/10.1016\/j.saa.2021.120436 (2022).","journal-title":"Spectrochim Acta Mol. Biomol. Spectrosc."},{"key":"6157_CR40","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.talanta.2018.01.013","volume":"181","author":"J P\u0142otka-Wasylka","year":"2018","unstructured":"P\u0142otka-Wasylka, J. A new tool for the evaluation of the analytical procedure: green analytical procedure index. Talanta 181, 204\u2013209. https:\/\/doi.org\/10.1016\/j.talanta.2018.01.013 (2018).","journal-title":"Talanta"},{"key":"6157_CR41","doi-asserted-by":"publisher","first-page":"120998","DOI":"10.1016\/j.saa.2022.120998","volume":"272","author":"MG Fawzy","year":"2022","unstructured":"Fawzy, M. G., Hassan, W. E., Mostafa, A. A. & Sayed, R. A. Different approaches for the assessment of greenness of spectrophotometric methodologies utilized for resolving the spectral overlap of newly approved binary hypoglycemic pharmaceutical mixture. Spectrochim Acta Mol. Biomol. Spectrosc. 272, 120998. https:\/\/doi.org\/10.1016\/j.saa.2022.120998 (2022).","journal-title":"Spectrochim Acta Mol. Biomol. Spectrosc."},{"key":"6157_CR42","doi-asserted-by":"publisher","unstructured":"Gamal Fawzy, M., Saleh, H., Reda, A. & Bahgat, E. A. A green spectrophotometric method for the simultaneous determination of nasal binary mixture used in respiratory diseases: applying isosbestic point and chemometric approaches as a resolving tool, greenness evaluation. Spectrochim Acta Mol. Biomol. Spectrosc. 121585. https:\/\/doi.org\/10.1016\/j.saa.2022.121585 (2022).","DOI":"10.1016\/j.saa.2022.121585"},{"key":"6157_CR43","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1007\/s13738-020-01897-z","volume":"17","author":"MM Ayad","year":"2020","unstructured":"Ayad, M. M., Hosny, M. M., Ibrahim, A. E., El-Abassy, O. M. & Belal, F. F. Development and validation of eco-friendly micellar HPLC method for the simultaneous determination of Hydrochlorothiazide and Valsartan in bulk powder and pharmaceutical dosage forms. J. Iran. Chem. Soc. 17, 1725\u20131730. https:\/\/doi.org\/10.1007\/s13738-020-01897-z (2020).","journal-title":"J. Iran. Chem. Soc."},{"key":"6157_CR44","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3390\/analytica5030030","volume":"5","author":"FR Mansour","year":"2024","unstructured":"MansourF.R., P\u0142otka-Wasylka, J. & Locatelli, M. Modified GAPI (MoGAPI) tool and software for the assessment of method greenness: case studies and applications. Analytica 5, 451\u2013457. https:\/\/doi.org\/10.3390\/analytica5030030 (2024).","journal-title":"Analytica"},{"key":"6157_CR45","doi-asserted-by":"publisher","first-page":"108829","DOI":"10.1016\/j.microc.2023.108829","volume":"191","author":"HM El-Sayed","year":"2023","unstructured":"El-Sayed, H. M. et al. Safinamide detection based on Prussian blue analogue modified Solid-contact potentiometric sensor. Microchem. J. 191, 108829. https:\/\/doi.org\/10.1016\/j.microc.2023.108829 (2023).","journal-title":"Microchem. J."},{"key":"6157_CR46","doi-asserted-by":"publisher","first-page":"10076","DOI":"10.1021\/acs.analchem.0c01887","volume":"92","author":"F Pena-Pereira","year":"2020","unstructured":"Pena-Pereira, F., Wojnowski, W. & Tobiszewski, M. AGREE - Analytical greenness metric approach and software. Anal. Chem. 92, 10076\u201310082. https:\/\/doi.org\/10.1021\/acs.analchem.0c01887 (2020).","journal-title":"Anal. Chem."},{"key":"6157_CR47","doi-asserted-by":"publisher","first-page":"123844","DOI":"10.1016\/j.saa.2024.123844","volume":"309","author":"OM El-Abassy","year":"2024","unstructured":"El-Abassy, O. M., Maged, K., El-Henawee, M. M. & Abd El-Hay, S. S. Development of eco-friendly spectrophotometric methods for analysis of Metformin hydrochloride and linagliptin in presence of Metformin toxic impurity in their pure and dosage forms: validation, practicality and greenness studies. Spectrochim Acta Mol. Biomol. Spectrosc. 309, 123844. https:\/\/doi.org\/10.1016\/j.saa.2024.123844 (2024).","journal-title":"Spectrochim Acta Mol. Biomol. Spectrosc."},{"key":"6157_CR48","doi-asserted-by":"publisher","unstructured":"Halim, M. K., Badran, O. M. & Abbas, A. E. F. Sustainable chemometric methods boosted by Latin hypercube technique for quantifying the recently FDA-approved combination of bupivacaine and meloxicam in the presence of bupivacaine carcinogenic impurity: comprehensive greenness, blueness, and whiteness. Microchem. J. 110276. https:\/\/doi.org\/10.1016\/j.microc.2024.110276 (2024).","DOI":"10.1016\/j.microc.2024.110276"},{"key":"6157_CR49","doi-asserted-by":"publisher","first-page":"464674","DOI":"10.1016\/j.chroma.2024.464674","volume":"1717","author":"M Ntorkou","year":"2024","unstructured":"Ntorkou, M., Kabir, A., Furton, K. G., Tzanavaras, P. D. & Zacharis, C. K. Sol-gel Carbowax 20\u00a0M-zwitterionic ionic liquid composite sorbent-based capsule phase Microextraction device combined with HPLC\/post-column derivatization for the determination of lanreotide, a human somatostatin analogue in urine. J. Chromatogr. A. 1717, 464674. https:\/\/doi.org\/10.1016\/j.chroma.2024.464674 (2024).","journal-title":"J. Chromatogr. A"},{"key":"6157_CR50","doi-asserted-by":"publisher","first-page":"116223","DOI":"10.1016\/J.TRAC.2021.116223","volume":"138","author":"PM Nowak","year":"2021","unstructured":"Nowak, P. M., Wietecha-Pos\u0142uszny, R. & Pawliszyn, J. White analytical chemistry: an approach to reconcile the principles of green analytical chemistry and functionality. TRAC Trends Anal. Chem. 138, 116223. https:\/\/doi.org\/10.1016\/J.TRAC.2021.116223 (2021).","journal-title":"TRAC Trends Anal. Chem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06157-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06157-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06157-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T15:55:19Z","timestamp":1750694119000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06157-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6157"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-06157-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,23]]},"assertion":[{"value":"7 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20252"}}